PRECLINICAL EVALUATION OF INTERMEDIATE ENDPOINTS AND THEIR MODULATIONBY CHEMOPREVENTIVE AGENTS



NIH GUIDE, Volume 23, Number 7, February 18, 1994



RFP AVAILABLE:  NCI-CN-45594-32



P.T. 34



Keywords:

  Cancer/Carcinogenesis 

  Disease Model 

  Chemopreventive Agents 

  Biological Markers 



National Cancer Institute



The National Cancer Institute is seeking contractors qualified to

perform animal cancer model studies of biomarkers and intermediate

endpoints that might be used in human clinical trials.  The work to

be performed will assess, in detail, the biomarker modulating effects

of selected chemopreventive compounds.  This solicitation is an

annual announcement to expand a current pool of Master Agreement (MA)

Holders qualified to perform this type of work.  Individual work

requirements will be defined as the need arises by Master Agreement

Orders issued during the period of performance, and Master Agreement

Orders will be awarded based on competition between members of the MA

pool.  The solicitation will be released on or about February 22,

1994 with proposals due April 23, 1994.



INQUIRIES



The Contracting Officer for this solicitation is Richard L. Hartmann

on telephone (301) 496-8603.  Copies of the RFP may be obtained by

sending a written request to:



Ms. Desiree Sylver-Foust

Research Contracts Branch

National Cancer Institute

Executive Plaza South, Room 635

Bethesda, MD  20892

Telephone:  (301) 496-8603



.


Return to 1994 Index

Return to NIH Guide Main Index


Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS)
  USA.gov - Government Made Easy


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.